Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
CAMBRIDGE, Mass., April 26, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation is scheduled for Wednesday, May 3rd at 10:00 a.m. ET.
A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
